Old drug, new hope: spironolactone may help kids with rare Autism-Linked gene mutations

NCT ID NCT06678685

Recruiting now Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether spironolactone, a common diuretic, can improve learning and behavior in children aged 3–10 with NCOR gene mutations, which are linked to autism spectrum disorder. Only 2 children will be enrolled, and researchers will measure changes in intelligence and autism symptoms. The drug is already used safely in children for other conditions, but this is an early exploratory trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: spironolactone
What this could lead to: If it works, this could point toward a treatment for learning and memory problems in children with certain NCOR gene mutations.
What could go wrong: This is a very small, early-stage trial with only 2 children, so results may not apply broadly. Spironolactone is generally safe but can affect potassium levels and blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial septal defect autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASD NCOR GENE MUTATIONS SPIRONOLACTONE

Contacts and locations

Locations

Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.